

IMPACT FACTOR 2.0





an Open Access Journal by MDPI

Advances of Phenylketonuria in Children

Guest Editors:

Dr. Eduardo Vieira Neto

Department of Pediatrics, School of Medicine, UPMC Children's Hospital of Pittsburgh, 4401 Penn Ave., Pittsburgh, PA 15224, USA

Prof. Dr. Márcia Gonçalves Ribeiro

Institute of Childcare and Pediatrics Martagão Gesteira/UFRJ, Federal University of Rio de Janeiro, Rio de Janeiro 21941-912, RJ, Brazil

Deadline for manuscript submissions: **31 January 2025**

Message from the Guest Editors

From1934 first detected phenyl pyruvic acid to 1963 a method for measuring phenylalanine from dried blood spots of newborns, it took almost 30 years. However, important drawbacks remain in the management of phenylketonuria (PKU) now. Adherence to dietary therapy, especially after the first decade of life, is often unsatisfactory, with consequences for neurocognitive function. Behavioral and emotional problems are still described in many continuously treated children and adolescents. The neuropathology of PKU remains a major knowledge gap. Sapropterin. an oral form tetrahydrobiopterin, is an alternative pharmacological treatment for a subset of patients with PKU, mainly those with mild or moderate metabolic phenotypes. It is not known whether pegylated phenylalanine ammonia lyase, which requires daily subcutaneous injections, is safe and effective in children.

Dr. Eduardo Vieira Neto Prof. Dr. Márcia Gonçalves Ribeiro *Guest Editors*













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Paul R. Carney

Departments of Child Health and Neurology, University of Missouri, 400 Keene Street, Columbia, MI 65201, USA

Message from the Editor-in-Chief

You are invited to contribute a research article or comprehensive review for consideration and publication in *Children* (ISSN 2227-9067). *Children* is an open access journal—research articles, reviews, and other content are published online immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. The journal focuses on sharing clinical, epidemiological, and translational science relevant to children's health. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (Pediatrics) / CiteScore - Q2 (Pediatrics, Perinatology and Child Health)

Contact Us